Recombinant CCR2 (Plozalizumab Biosimilar) anticorps
Research Grade
Reactivité: Humain
ELISA
Hôte: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Antigène Tous les produits CCR2 (Plozalizumab Biosimilar)
- CCR2 (Plozalizumab Biosimilar)
- Type d'anticorp
- Recombinant Antibody
- Reactivité
- Humain
-
Hôte
-
Mammalian Cells
- Expression System
- Mammalian cells
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp CCR2 (Plozalizumab Biosimilar) est non-conjugé
- Application
- ELISA
- Fonction
- Plozalizumab Biosimilar - Anti-CCR2, CD192 mAb
- Attributs du produit
- Antibody Type: IgG1-kappa
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Classe de qualité
- Research Grade
- Isotype
- IgG1 kappa
-
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS pH 7.5
- Stock
- -80 °C
- Stockage commentaire
- store at -80°C
-
- Antigène
- CCR2 (Plozalizumab Biosimilar)
- Abstract
- CCR2 (Plozalizumab Biosimilar) Produits
- Classe de substances
- Biosimilar
- Sujet
-
MLN-1202,anti-CCR2,hu1D9
Plozalizumab is a humanized monoclonal antibody that targets CCR2 chemokine receptors found on the surface of white blood cells such as macrophages and monocytes. Plozalizumab has been investigated to treat Atherosclerosis. CCR2 is supposed to play an important role in the trafficking of monocytes and macrophages to sites of inflammation. - Numéro CAS
- 1610761-46-0
-
Vous êtes ici:
